Whalesbook
Poora market pichhle 5 mahine se double-digit growth dikha raha hai, but real picture thoda alag hai. Yeh growth basically daawaon ke rate badhane aur naye products launch karne se aa rahi hai, na ki zyada log bimari se lad rahe hain isliye. Yeh trend cardiac, respiratory aur khaas kar anti-diabetic drugs mein zyada dikh raha hai.
Anti-Diabetic Segment Mein Toofani Tezi!
Ismein sabse interesting hai anti-diabetic segment. April 2026 mein iski sales ₹2,000 crore cross kar gayi, jo pichhle saal ₹1,795 crore thi. Yeh segment, anti-infectives, gastro-intestinal aur cardiac drugs ke saath market ko lead kar raha hai. Anti-diabetics mein toh 16% ki toofani growth hui hai, aur inka market share 60 basis points badh gaya. Yeh sab hua hai semaglutide ka patent March 2026 mein expire hone ke baad. Nomura ka kehna hai ki 13 companies ne generic semaglutide launch kiya hai aur April mein hi ₹44 crore kama liye. Year-end tak yeh ₹528 crore tak ja sakta hai. Analysts ko lagta hai ki volumes bhi badhengi jab yeh generics India mein aur zyada popularity paayenge.
Generic Semaglutide Ne Machaya Dhamal!
Semaglutide patent expiry ka asli impact ab dikh raha hai. Bas kuch hi hafton mein 25 se zyada generic brands aa gaye hain diabetes aur weight-loss ki race mein. Torrent Pharma ne toh 38% market share pakad li hai aur April mein ₹17 crore ki sales ki hai. Zydus, Lupin, Dr. Reddy's, Eris, Alkem bhi peeche nahi hain. Is competition ki wajah se prices kaafi kam ho gaye hain, aur GLP-1 agonist market ka turnover ₹545 crore (April 2025) se ₹1,736 crore (April 2026) ho gaya hai – matlab 3 guna se bhi zyada! Is sab pressure ke bawajood, Eli Lilly ka Mounjaro abhi bhi top brand hai aur saal bhar mein ₹1,000 crore se zyada kama raha hai. Yeh dikhata hai ki demand itni strong hai ki naye prices hone par bhi alag-alag brands saath mein tik sakte hain.
Company Performance Aur Market Pressure
Bade players ki baat karein toh, India ki sabse badi pharma company, Sun Pharma, ne April mein 15% sales growth report ki hai. Iska P/E ratio 40.31 hai, jo Nifty Pharma index ke average 35.7 se upar hai. Analysts ne isko 'Buy' kaha hai aur 6.40% tak ka upside expect kar rahe hain. Eli Lilly ka P/E ratio bhi 33.69 ke aas-paas hai. Torrent Pharma aur Corona Remedies ke P/E ratios toh aur bhi high hain, jo high growth expectations dikha rahe hain. Overall situation mixed hai. Growth toh hai, but yeh basically prices par depend kar rahi hai kyuki volumes zyada nahi badh rahi. Nomura ne bataya ki March 2026 mein, 5.5% growth price se, 3.5% new products se aur sirf 1.1% volumes se aayi thi. Energy jaise raw material ke costs badhne se bhi pressure aa raha hai, jisse shayad aur price hikes ho sakte hain.
Growth Ki Sustainability Par Sawal?
Par ek badi chinta yeh hai ki yeh growth kitni sustainable hai. Jab growth sirf price badhane ya generics lane se ho, aur naye patients na juden, toh long-term mein problem ho sakti hai. Energy aur petrochemicals ke badhte costs margins par pressure dal rahe hain. Essential medicines ke liye April 2026 mein thoda price hike allowed hai, but shayad woh poore badhte kharch ko cover na kar paaye. Generic semaglutide ki jaldi entry ne prices ko kam kiya hai, but sab companies ke margins bhi kam ho rahe hain. Jab bhi patent expire hota hai, prices girte hain aur generics market share badha lete hain – yeh trend continue hone wala hai. Jin companies ke paas zyada products nahi hain, ya jo single blockbuster drugs par depend karti hain, unke liye revenue risk badh gaya hai. Plus, India ka 74% se zyada API import China se hota hai, isliye supply chain issues aur price fluctuations ka khatra hamesha bana rehta hai.
Aage Kya Hoga Pharma Market Mein?
Future mein market aur develop hoga, especially weight-loss drugs mein. Injectables ke saath-saath oral medications par bhi focus rahega. Nomura ko strong pipelines wali companies pasand hain, aur woh Sun Pharma ko 'Buy' rating de rahe hain, unke scale aur diversification ke wajah se. Baaki analysts bhi Sun Pharma ko 'Buy' recommend kar rahe hain, moderate upside expect karte hue. Eli Lilly manufacturing mein invest kar rahi hai, jo future volume growth par unka confidence dikhata hai, especially obesity treatments mein, prices ka pressure hone ke bawajood. Generics aur price-sensitive market ki taraf shift hone ka matlab hai ki companies ko consistent profits ke liye innovation aur cost efficiency par focus karna padega.